Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is up 2.1% since the beginning of the year. At $8 per share, CRBP is trading 59.6% below its 52-week high of $21. Investors who bought $1,000 worth of CRBP shares 5 years ago would now be looking at an investment worth $139.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has returned 2.09% so far this year and 0.85% over the past 12 months. Over the last ten years, CRBP has returned -21.17% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Nov 11, 2014, CRBP's average daily return is +0.18%, while the average monthly return is +3.17%. At this rate, an investment would double in approximately 1.9 years.

Historically, 46% of months were positive and 54% were negative. The best month was Jan 2024 with a return of +338.6%, while the worst month was Sep 2020 at -80.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, CRBP closed higher 45% of trading days. The best single day was Jan 26, 2024 with a return of +249.4%, while the worst single day was Sep 8, 2020 at -75.9%.

Corbus Pharmaceuticals Holdings, Inc. has an annualized alpha of 32.13%, beta of 1.31, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 11, 2014.

• This stock participated in 234.58% of S&P 500 Index downside but only 179.66% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRBP ranks 44 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Corbus Pharmaceuticals Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corbus Pharmaceuticals Holdings, Inc. was 99.31%, occurring on Mar 10, 2023. The portfolio has not yet recovered.

The current Corbus Pharmaceuticals Holdings, Inc. drawdown is 97.32%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Corbus Pharmaceuticals Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Corbus Pharmaceuticals Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.